HYDERABAD (January 26, 2016) — MMS Holdings Inc. (www.mmsholdings.com) is pleased to announce the opening of a new office in Hyderabad, India.
The company’s Asia headquarters are located in Bangalore, India and the company’s ability to deliver exceptional quality across all of its service offerings has resulted in steady growth for the company.
According to Prasad Koppolu, Vice President for MMS Holdings Inc., “Our clients have come to depend on us to deliver quality across all of our global office locations and India is no exception. Our presence in both Bangalore and Hyderabad will allow MMS to better serve our global client base by providing greater access to the experienced life sciences talent in this region.”
With its cross-functional staff already in place, the Hyderabad center is expected to be fully operational by early spring 2016.
About MMS Holdings Inc.
MMS Holdings Inc. (www.mmsholdings.com) is a global clinical research organization (CRO) that focuses on regulatory submission support for the pharmaceutical and biotech industries. Our strong industry experience and scientific approach to drug development makes us a valuable partner in creating compelling submissions that meet rigorous regulatory standards. MMS’ clients span from top 10 pharma to virtual biotechs, and we support each one with the same standard of excellence. Our core service areas include medical and regulatory writing, biostatistics, clinical programming, data management, clinical development, clinical trial disclosure, regulatory affairs, regulatory submissions and pharmacovigilance. Our mission is to deliver high-quality services, rooted in good science and decades of regulatory experience, that will assist our clients in developing and marketing life-changing therapies, thereby positively affecting patients’ lives worldwide.